



(51) International Patent Classification:  
C09B 11/00 (2006.01) A61K 49/00 (2006.01)

(21) International Application Number:  
PCT/US2024/015099

(22) International Filing Date:  
09 February 2024 (09.02.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
63/484,312 10 February 2023 (10.02.2023) US

(71) Applicant: VANDERBILT UNIVERSITY [US/US]; 305  
Kirkland Hall, 2201 West End Avenue, Nashville, Ten-  
nessee 37240 (US).

(72) Inventor: CHOI, Eunyung; c/o Vanderbilt University,  
305 Kirkland Hall, 2201 West End Avenue, Nashville, Ten-  
nessee 37240 (US).


(74) Agent: BRANDT, Anthony C. et al.; Michael Best &  
Friedrich LLP, 790 N. Water Street, Suite 2500, Milwaukee,  
Wisconsin 53202 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,  
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,  
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,  
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,  
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, CV,  
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,  
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,  
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: CONJUGATED METABOLITES FOR CANCER DETECTION AND TREATMENT

FIG. 1



(57) Abstract: Disclosed herein are compounds, research tools, and methods for detecting and treating epithelial cell dysplasia, precancer, and cancer in a cell or a subject. Also disclosed herein are compounds, research tools, and methods for inhibiting a dysplastic cell, inhibiting the transition of a metaplastic cell to a dysplastic cell, and reducing the incidence of carcinoma in a cell or a subject. In some embodiments, the compounds, research tools, and methods comprise an eicosenoic acid conjugate compound. In some embodiments, the compounds, research tools, and methods comprise a therapy comprising an SCD1 enzyme inhibitor.

[Continued on next page]

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,  
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,  
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- *without international search report and to be republished  
upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*